ABSTRACT
Patients with severe asthma have asthma symptoms which are difficult to control, require high dosages of medication, and continue to experience persistent symptoms, asthma exacerbations or airflow obstruction. Epidemiological and clinical evidences point to the fact that severe asthma is not a single phenotype. Cluster analyses have identified subclasses of severe asthma using parameters such as patient characteristics, and cytokine profiles have also been useful in classifying moderate and severe asthma. The IL-4/IL-13 signalling pathway accounts for the symptoms experienced by a subset of severe asthmatics with allergen-associated symptoms and high serum immunoglobulin E (IgE) levels, and these patients are generally responsive to anti-IgE treatment. The IL-5/IL-33 signalling pathway is likely to play a key role in the disease pathogenesis of those who are resistant to high doses of inhaled corticosteroid but responsive to systemic corticosteroids and anti-IL5 therapy. The IL-17 signalling pathway is thought to contribute to 'neutrophilic asthma'. Although traditionally viewed as players in the defence mechanism against viral and intracellular bacterial infection, mounting evidence supports a role for Th1 cytokines such as IL-18 and IFN-γ in severe asthma pathogenesis. Furthermore, these cytokine signalling pathways interact to contribute to the spectrum of clinical pathological outcomes in severe asthma. To date, glucocorticoids are the most effective anti-asthma drugs available, yet severe asthma patients are typically resistant to the effects of glucocorticoids. Glucocorticoid receptor dysfunction and histone deacetylase activity reduction are likely to contribute to glucocorticoid resistance in severe asthma patients. This review discusses recent development in different cytokine signalling pathways, their interactions and steroid resistance, in the context of severe asthma pathogenesis.
Subject(s)
Asthma/etiology , Acetylation , Animals , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Cytokines/genetics , Cytokines/immunology , Cytokines/metabolism , Drug Resistance , Glucocorticoids/therapeutic use , Histones/metabolism , Humans , Severity of Illness Index , Signal TransductionABSTRACT
Reduced infection by mycobacteria, including Mycobacterium tuberculosis, may be partly responsible for increased prevalence of allergic and autoimmune diseases in developed countries. In a murine model of innate resistance to mycobacteria, the Nramp1 gene has been shown to affect asthma susceptibility. From this observation, it was proposed that human NRAMP1 may be a modulator of asthma risk in human populations. To experimentally test the candidacy of NRAMP1 in asthma susceptibility, we characterized five genetic variants of NRAMP1 (5'CAn, 274C>T, 469+14G>C, D543N, and 1729+del4) in an asthma family-based cohort from northeastern Quebec. We did not observe any significant association between NRAMP1 variants (either allele or haplotype specific) with asthma, atopy, or serum immunoglobulin E levels. These results demonstrate that, in spite of direct involvement of Nramp1 in a murine asthma model, in human populations NRAMP1 is not likely to be a major contributor to the genetic etiology of asthma and asthma-related phenotypes.
Subject(s)
Asthma/genetics , Cation Transport Proteins/genetics , Genetic Predisposition to Disease , Hypersensitivity, Immediate/genetics , Polymorphism, Single Nucleotide , Canada , Genotype , Haplotypes , Humans , Immunoglobulin E/blood , White People/geneticsSubject(s)
Arthritis, Infectious/complications , Chickenpox/complications , Hip Joint/microbiology , Knee Joint/microbiology , Myositis/microbiology , Skin Diseases, Bacterial/complications , Streptococcal Infections/complications , Streptococcus pyogenes , Cellulitis/microbiology , Child, Preschool , Fasciitis/microbiology , Female , Femur/microbiology , Humans , Magnetic Resonance Imaging , ThighABSTRACT
A nonparametric estimator for the survival function, accommodating censored survival times and uncertainty in the assignment of cause of death, is proposed. For example, in a carcinogenicity experiment the data on each animal may consist of an observed age-at-death and some indication of the probability that the tumor type under study caused death. An estimator of the net survival function, for time-to-death due to the cause of interest, is developed. Under certain assumptions, the proposed estimator is consistent and asymptotically normally distributed. Monte Carlo simulations were used to compare this estimator with the Kaplan-Meier estimator. Forcing the cause of death to be specified with certainty, as required by the Kaplan-Meier estimator, may result in substantial biases.